



Partnering with The Vaccine Fund

January 2005

# Progress Report

to the  
Global Alliance for Vaccines and Immunization (GAVI)  
and  
The Vaccine Fund

by the Government of Turkmenistan

COUNTRY:

Date of submission: April, 10

Reporting period: 2004 ( Information provided in this report **MUST** refer to 2004 activities )

( Tick only one ) :

|                                     |                                  |
|-------------------------------------|----------------------------------|
| Inception report                    | <input type="radio"/>            |
| First annual progress report        | <input type="radio"/>            |
| Second annual progress report       | <input type="radio"/>            |
| <b>Third annual progress report</b> | <input checked="" type="radio"/> |
| Fourth annual progress report       | <input type="radio"/>            |
| Fifth annual progress report        | <input type="radio"/>            |

*Text boxes supplied in this report are meant only to be used as guides. Please feel free to add text beyond the space provided.*

***\*Unless otherwise specified, documents may be shared with GAVI partners and collaborators***

## **Progress Report Form: Table of Contents**

### **1. Report on progress made during 2004**

- 1.1 Immunization Services Support (ISS)
  - 1.1.1 Management of ISS Funds
  - 1.1.2 Use of Immunization Services Support
  - 1.1.3 Immunization Data Quality Audit
- 1.2 GAVI/Vaccine Fund New and Under-used Vaccines
  - 1.2.1 Receipt of new and under-used vaccines
  - 1.2.2 Major activities
  - 1.2.3 Use if GAVI/The Vaccine Fund financial support (US\$100,000) for introduction of the new vaccine
- 1.3 Injection Safety
  - 1.3.1 Receipt of injection safety support
  - 1.3.2 Progress of transition plan for safe injections and safe management of sharps waste
  - 1.3.3 Statement on use of GAVI/The Vaccine Fund injection safety support (if received in the form of a cash contribution)

### **2. Financial Sustainability**

### **3. Request for new and under-used vaccine for 2006**

- 3.1 Up-dated immunization targets
- 3.2 Confirmed/revised request for new vaccine (to be shared with UNICEF Supply Division) for year...
- 3.3 Confirmed/revised request for injection safety support for the year...

### **4. Please report on progress since submission of the last Progress Report based on the indicators selected by your country in the proposal for GAVI/VF support**

### **5. Checklist**

### **6. Comments**

### **7. Signatures**

## 1. Report on progress made during 2004

To be filled in by the country for each type of support received from GAVI/The Vaccine Fund.

### 1.1 Immunization Services Support (ISS) n/a

#### 1.1.1 Management of ISS Funds

*Please describe the mechanism for management of ISS funds, including the role of the Inter-Agency Co-ordinating Committee (ICC).  
Please report on any problems that have been encountered involving the use of those funds, such as delay in availability for programme use.*

### 1.1.2 Use of Immunization Services Support

In 2004, the following major areas of activities have been funded with the GAVI/Vaccine Fund **Immunization Services Support** contribution.

Funds received during 2004 \_\_\_\_\_  
 Remaining funds (carry over) from 2003 \_\_\_\_\_

**Table 1: Use of funds during 2004**

| Area of Immunization Services Support | Total amount in US \$ | AMOUNT OF FUNDS |                       |          |                        |
|---------------------------------------|-----------------------|-----------------|-----------------------|----------|------------------------|
|                                       |                       | PUBLIC SECTOR   |                       |          | PRIVATE SECTOR & Other |
|                                       |                       | Central         | Region/State/Province | District |                        |
| Vaccines                              |                       |                 |                       |          |                        |
| Injection supplies                    |                       |                 |                       |          |                        |
| Personnel                             |                       |                 |                       |          |                        |
| Transportation                        |                       |                 |                       |          |                        |
| Maintenance and overheads             |                       |                 |                       |          |                        |
| Training                              |                       |                 |                       |          |                        |
| IEC / social mobilization             |                       |                 |                       |          |                        |
| Outreach                              |                       |                 |                       |          |                        |
| Supervision                           |                       |                 |                       |          |                        |
| Monitoring and evaluation             |                       |                 |                       |          |                        |
| Epidemiological surveillance          |                       |                 |                       |          |                        |
| Vehicles                              |                       |                 |                       |          |                        |
| Cold chain equipment                  |                       |                 |                       |          |                        |
| Other ..... (specify)                 |                       |                 |                       |          |                        |
| <b>Total:</b>                         |                       |                 |                       |          |                        |
| <b>Remaining funds for next year:</b> |                       |                 |                       |          |                        |

*\*If no information is available because of block grants, please indicate under 'other'.*

Please attach the minutes of the ICC meeting(s) when the allocation of funds was discussed.

Please report on major activities conducted to strengthen immunization, as well as, problems encountered in relation to your multi-year plan.

**1.1.3 Immunization Data Quality Audit (DQA)** (If it has been implemented in your country)

Has a plan of action to improve the reporting system based on the recommendations from the DQA been prepared?  
If yes, please attach the plan.

YES

NO

If yes, please report on the degree of its implementation.

Please attach the minutes of the ICC meeting where the plan of action for the DQA was discussed and endorsed by the ICC.

Please report on studies conducted regarding EPI issues during 2004 (for example, coverage surveys).

## 1.2 GAVI/Vaccine Fund New & Under-used Vaccines Support

### 1.2.1 Receipt of new and under-used vaccines during 2004

**Start of vaccinations with the new and under-used vaccine:      MONTH January      YEAR 2002.**

**Hepatitis B vaccine has been introduced since January 2002**

*Please report on receipt of vaccines provided by GAVI/VF, including problems encountered.*

In 2004 within the framework of GAVI and Vaccine Fund support received 213, 700 doses of HepB vaccine for newborns, including 119,300 doses in 1-dose vials and 94,400 doses in 10-doses vials. Also in December 2003 received AD syringes in amount of 271,600 and 2,950 Safety boxes.

### 1.2.2 Major activities

*Please outline major activities that have been or will be undertaken, in relation to, introduction, phasing-in, service strengthening, etc. and report on problems encountered.*

- Sustained high immunization coverage (more than 95% by all EPI antigens)
- During 2004 year new national Immunization programme for 2003-2020 and relevant Order of the Ministry of health have been introduced:
  - updated vaccination calendar in accordance with WHO recommendations and country certification as polio free, foresee eventuality of introduction of new and polyvalent combined vaccines;
  - expanded indications for vaccination;
  - updated policy of storage, transportation of cold vaccines;
  - everywhere introduced Open Vial policy;

- changed anatomic places for vaccination.
- More than 180 managers and health specialists were familiarised with New National programme on Immunization and order of the MoH on introduction.
- With UNICEF support 180 health workers (epidemiologists, immunologists, family doctors and teacher of medical schools) trained on Safe Immunisation practices, conducted training for 93 epidemiologists (responsible for vaccines warehouses) on proper vaccine storage according to cold chain requirements.
- With UNICEF support printed collection of National programmes and orders of the MoH related to Immunization and vaccination calendar in amount of 3- and 5- thousand correspondingly and distributed to health facilities.
- In 2004 WHO experts assessed Central Vaccines Warehouse and noted 85% relevance to requirement for vaccine storage at national level.
- Carry out monthly state statistical reporting on Immunization
- Carry out regular epidemiological surveillance of vaccine-preventable diseases with monthly statistical reporting and active surveillance of AFPs within the framework of sustainability of status of the country as polio free.
- With UNICEF support strengthened surveillance through introduction of computerised system for monitoring of implementation of Immunization programme at national and sub-national levels, installed local area network between Centre and *velayats* (provinces).
- Financial sustainable plan on Immunization updated by National Working Group and a second time it was submitted for signature of the Minister of Economics and Finance.
- In accordance with VII agreement between MoH and UNICEF purchased and procured vaccines for vaccination and revaccination of children according to National vaccination calendar.

Challenges:

- Absence of National vaccine quality control agency in the country.
- Lack of AEFI surveillance and reporting on cases.
- In spite of high vaccination coverage need to improve communication work on Immunization for parents on benefits and purpose of vaccination.
- High wastage factor is due because of low density of population

### **1.2.3 Use of GAVI/The Vaccine Fund financial support (US\$100,000) for the introduction of the new vaccine**

*Please report on the proportion of 100,000 US\$ used, activities undertaken, and problems encountered such as delay in availability of funds for programme use.*

### 1.3 Injection Safety

#### 1.3.1 **Receipt of injection safety support**

*Please report on receipt of injection safety support provided by GAVI/VF, including problems encountered*

In early 2004 Ministry of Health received GAVI Secretariat approval for safety injection support. Within the framework of the support by MoH received 122400 AD syringes for BCG, 12300 reconstitution syringes for BCG, 19500 reconstitution syringes for Measles vaccine, 487,800 AD syringes for vaccination and 7125 safety boxes.

Receipt of syringes in October instead of expected earlier dates of delivery cause to absence of stock of AD syringes in Central Warehouse during one month.



|   |  |  |  |   |
|---|--|--|--|---|
| <ul style="list-style-type: none"> <li>➤ Proportion of vaccination points, equipped with disposal syringes for reconstitution – target 100%</li> <li>➤ Proportion of vaccination points (facilities providing vaccination more than twice in a month) – target 100% by 2005</li> <li>➤ Proportion of vaccination points, supplied with adequate sterile means for injection (integrity of package, expiry date) – target 100% by 2005</li> <li>➤ Proportion of health facilities provided with adequate quantity of safety boxes (one safety box in use, and at least another one on stock) – target 100% by 2004</li> <li>➤ Availability of an incinerator or non</li> </ul> | <p><b><i>2. Adequacy of disposal of used injection equipment</i></b></p> | <p>All vaccination points have in stock AD syringes for infants vaccination</p> <p>All vaccination points have stock of AD and disposable syringes vaccination and for other issues such as antishock therapy</p> <p>All vaccination points have safety boxes for safe waste disposal of used injection equipment, which then open burned.</p> <p>Safety boxes mainly are burning openly by responsible person in accordance with instruction. In places where incinerators exist - in incinerators.</p> |  | <p>Approval of VF and GAVI Secretariat safe injection materials for vaccination will gave opportunity for procurement of AD syringes for revaccination from state budget.</p> |
|---|--|--|--|---|

|  |   |   |  |  |
|--|---|---|--|--|
| <p>incineration safe facility – target 100% by 2004</p> <p>➤ Proportion of health facilities with presence of used syringes and needles in garbage, dumping areas or close to the health facility attributable to vaccination (i.e. ADs) – target 0% by 2005</p> <p>➤ Number of abscesses following immunization injection reported</p> <p>➤ Proportion of immunization injections observed as following aseptic injection technique (supervision reports, SIP assessment) – target 95% by 2005</p> <p>Proportion of vaccination injection given in the recommended site – target 90% by 2006, 99% by 2008</p> | <p><b>3. Sterility of injections in immunization</b></p> <p><b>4. Anatomic sites of injection for vaccination</b></p> | <p>Achieved.<br/>By national programme and Minister’s order strictly prohibited to waste used syringes and needles to garbage and trash dump and use them for secondary waste processing.</p> <p>Sanitary epidemiological service is assigned for inspection of the order implementation to the point of fine.</p> <p>Not registered during reporting year</p> <p>Achieved, need to sustain</p> |  |  |
|--|---|---|--|--|

**1.3.3 Statement on use of GAVI/The Vaccine Fund injection safety support (if received in the form of a cash contribution)**

*The following major areas of activities have been funded (specify the amount) with the GAVI/The Vaccine Fund injection safety support in the past year:*

**2. Financial sustainability**

Inception Report: Outline timetable and process for the development of a financial sustainability plan . Describe assistance that may be needed for developing a financial sustainability plan.

First Annual Progress Report: Submit completed financial sustainability plan by given deadline. Describe major strategies for improving financial sustainability.

Subsequent Progress Reports: According to current GAVI rules, support for new and under-used vaccines is covering the total quantity required to meet country targets (assumed to be equal to DTP3 targets) over a five year period (100% x 5 years = 500%). If the requested amount of new vaccines does not target the full country in a given year (for example, a phasing in of 25%), the country is allowed to request the remaining (in that same example: 75%) in a later year. In an attempt to help countries find sources of funding in order to attain financial sustainability by slowly phasing out GAVI/VF support, they are encouraged to begin contributing a portion of the vaccine quantity required. Therefore, GAVI/VF support can be spread out over a maximum of ten years after the initial approval, but will not exceed the 500% limit (see figure 4 in the GAVI Handbook for further clarification). In table 2.1, specify the annual proportion of five year GAVI/VF support for new vaccines that is planned to be spread-out over a maximum of ten years and co-funded with other sources. **Please add the three rows (Proportion funded by GAVI/VF (%), Proportion funded by the Government and other sources (%), Total funding for ..... (new vaccine)) for each new vaccine.**

**Table 2.1: Sources (planned) of financing of new vaccine ..... (specify)**

| Proportion of vaccines supported by *                        | Annual proportion of vaccines |      |      |      |      |      |      |      |      |      |
|--|-------------------------------|------|------|------|------|------|------|------|------|------|
|  | 20..**                        | 20.. | 20.. | 20.. | 20.. | 20.. | 20.. | 20.. | 20.. | 20.. |
| A: Proportion funded by GAVI/VF (%)***                       |                               |      |      |      |      |      |      |      |      |      |
| B: Proportion funded by the Government and other sources (%) |                               |      |      |      |      |      |      |      |      |      |
| C: Total funding for ..... (new vaccine)                     |                               |      |      |      |      |      |      |      |      |      |

\* Percentage of DTP3 coverage (or measles coverage in case of Yellow Fever) that is target for vaccination with a new and under-used vaccine.

\*\* The first year should be the year of GAVI/VF new vaccine introduction

\*\*\* Row A should total 500% at the end of GAVI/VF support

In table 2.2 below, describe progress made against major financial sustainability strategies and corresponding indicators.

**Table 2.2: Progress against major financial sustainability strategies and corresponding indicators**

| Financial Sustainability Strategy   | Specific Actions Taken Towards Achieving Strategy | Progress Achieved | Problems Encountered        | Baseline Value of Progress Indicator | Current Value of Progress Indicator | Proposed Changes To Financial Sustainability Strategy |
|---|---|-------------------|-----------------------------|--------------------------------------|-------------------------------------|---|
| 1. Review the results/balance of annual financing of immunization of ICC meeting  |   | reviewed          |                             |                                      |                                     |   |
| 2. To make provision for reserve funds for foreseen expenditures for Immunization programme during annual budget planning |   | Planned in 2003.  |                             |                                      |                                     |   |
| 3. To develop and approve "Long-term financial plan   |   | developed         | Submitted for review to the |                                      |                                     |   |

|   |  |                 |  |     |     |   |
|---|--|-----------------|--|-----|-----|---|
| of national Immunization programme, including funding sources”  |  |                 | Ministry of economics and finance                                  |     |     |   |
| 4. Obligatory allocation of funds to cover expenses related to immunization in total budget for health since 2004 |  | foreseen        |  |     |     | Foreseen in Financial Sustainable plan of Immunization  |
| 5. Procurement vaccines through UNICEF in accordance with international costs                                     |  | achieved        |  |     |     | Extension of the MoU on vaccine procurement from 2006 to 2009   |
| 6. Proportion of vaccine’s wastage factor cannot be higher levels planned   |  | achieved        | In some etrap waster factor higher than it was planned             | 20% | 20% | Organization of mobile teams provided with transportation for collection of children in one vaccination point.      |
| 7. Procurement of vaccines, recommended by WHO  |  | achieved partly | Some vaccines procured for revaccination were not certified by WHO | 50% | 37% | It is planning to include in VII agreement with UNICEF all vaccine, including vaccines for revaccination since 2006 |

### 3. Request for new and under-used vaccines for year 2006

Section 3 is related to the request for new and under used vaccines and injection safety for 2006.

#### 3.1. Up-dated immunization targets

Confirm/update basic data approved with country application: figures are expected to be consistent with those reported in the WHO/UNICEF Joint Reporting Forms. Any changes and/or discrepancies **MUST** be justified in the space provided (page 12). Targets for future years **MUST** be provided.

**Table 3 : Update of immunization achievements and annual targets**

| Number of  | Achievements and targets |         |         |      |      |      |      |      |      |
|--|--------------------------|---------|---------|------|------|------|------|------|------|
|  | 2004                     | 2005    | 2006    | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 |
| <b>DENOMINATORS</b>  |                          |         |         |      |      |      |      |      |      |
| Births   | 89,934                   | 100,000 | 113,730 |      |      |      |      |      |      |
| Infants' deaths  | 1176                     | 1489    | 1523    |      |      |      |      |      |      |
| Surviving infants  | 88,758                   | 98511   | 122,207 |      |      |      |      |      |      |
| Infants vaccinated in 2004 (JRF) / to be vaccinated in 2005 and beyond with 1 <sup>st</sup> dose of DTP (DTP1)*                  | 87,160                   | 96,540  | 110,748 |      |      |      |      |      |      |
| Infants vaccinated 2004 (JRF) / to be vaccinated in 2005 and beyond with 3 <sup>rd</sup> dose of DTP (DTP3)*                     | 86,273                   | 95,555  | 108,840 |      |      |      |      |      |      |
| <b>NEW VACCINES **</b>   |                          |         |         |      |      |      |      |      |      |
| Infants vaccinated 2004 (JRF) / to be vaccinated in 2005 and beyond with 1 <sup>st</sup> dose of DTP (DTP1)* ..... (new vaccine) | 89,664                   | 99,700  | 110,748 |      |      |      |      |      |      |
| Infants vaccinated 2004 (JRF) / to be vaccinated in 2005 and beyond with 3 <sup>rd</sup> dose of..... (new vaccine)              | 85,651                   | 95,555  | 108,840 |      |      |      |      |      |      |
| Wastage rate in 2004 and plan for 2005 beyond*** ..... (new vaccine)   | 19,9                     | 19,0    | 19,0    |      |      |      |      |      |      |

**INJECTION SAFETY\*\*\*\***

|  |        |        |         |  |  |  |  |  |  |
|--|--------|--------|---------|--|--|--|--|--|--|
| Pregnant women vaccinated in 2004 (JRF) / to be vaccinated in 2005 and beyond with TT2 |        |        |         |  |  |  |  |  |  |
| Infants vaccinated in 2004 (JRF) / to be vaccinated in 2005 and beyond with BCG *      | 89,125 | 98,000 | 108,840 |  |  |  |  |  |  |
| Infants vaccinated in 2004 (JRF) / to be vaccinated in 2005 and beyond with Measles *  | 78,538 | 95,555 | 110,748 |  |  |  |  |  |  |

\* Indicate actual number of children vaccinated in 2004 and updated targets (with either DTP alone or combined)

\*\* Use 3 rows (as indicated under the heading **NEW VACCINES**) for every new vaccine introduced

\*\*\* Indicate actual wastage rate obtained in past years

\*\*\*\* Insert any row as necessary

*Please provide justification on changes to baseline, targets, wastage rate, vaccine presentation, etc. from the previously approved plan, and on reported figures which differ from those reported in the WHO/UNICEF Joint Reporting Form in the space provided below.*

### 3.2 Availability of revised request for new vaccine (to be shared with UNICEF Supply Division) for 2006

*In case you are changing the presentation of the vaccine, or increasing your request; please indicate below if UNICEF Supply Division has assured the availability of the new quantity/presentation of supply.*

**Table 4: Estimated number of doses of Hepatitis B vaccine (specify for one presentation only): Please repeat this table for any other vaccine presentation requested from GAVI/The Vaccine Fund**

|   | Formula                            | For 2006 |
|---|------------------------------------|----------|
| <b>A</b> Infants vaccinated/to be vaccinated with 1st dose of Hepatitis B vaccine (new vaccine)*                            |                                    | 113,730  |
| <b>B</b> Percentage of vaccines requested from The Vaccine Fund taking into consideration the Financial Sustainability Plan | %                                  | 75%      |
| <b>C</b> Number of doses per child  |                                    | 3        |
| <b>D</b> Number of doses  | $A \times B \times C$              | 255,893  |
| <b>E</b> Estimated wastage factor   | (see list in table 3)              | 1.25     |
| <b>F</b> Number of doses (incl. Wastage)  | $A \times C \times E \times B/100$ | 319,866  |
| <b>G</b> Vaccines buffer stock  | $F \times 0.25$                    | 79,966   |
| <b>H</b> Anticipated vaccines in stock at start of year 2006 (including balance of buffer stock)                            |                                    |          |
| <b>I</b> Total vaccine doses requested  | $F + G - H$                        | 399,832  |
| <b>J</b> Number of doses per vial   |                                    | 1        |
| <b>K</b> Number of AD syringes (+10% wastage)   | $(D + G - H) \times 1.11$          | 372,803  |
| <b>L</b> Reconstitution syringes(+10% wastage)  | $I/J \times 1.11$                  |          |
| <b>M</b> Total safety boxes (+10% of extra need)  | $(K + L) / 100 \times 1.11$        | 4,138    |

**ICC note: considering low density of population and sparseness of vaccination points need to delivery of 50% of vaccine in 1-dose vials, i.e. 199,916 doses**

*\*Please report the same figure as in table 3.*

**Table 5: Wastage rates and factors**

|                           |      |      |      |      |      |      |      |      |      |      |      |      |
|---------------------------|------|------|------|------|------|------|------|------|------|------|------|------|
| Vaccine wastage rate      | 5%   | 10%  | 15%  | 20%  | 25%  | 30%  | 35%  | 40%  | 45%  | 50%  | 55%  | 60%  |
| Equivalent wastage factor | 1.05 | 1.11 | 1.18 | 1.25 | 1.33 | 1.43 | 1.54 | 1.67 | 1.82 | 2.00 | 2.22 | 2.50 |

### Remarks

- **Phasing:** Please adjust estimates of target number of children to receive new vaccines, if a phased introduction is intended. If targets for hep B3 and Hib3 differ from DTP3, explanation of the difference should be provided
- **Wastage of vaccines:** Countries are expected to plan for a maximum of: 50% wastage rate for a lyophilized vaccine in 10 or 20-dose vial; 25% for a liquid vaccine in a 10 or 20-dose vial; 10% for any vaccine (either liquid or lyophilized) in 1 or 2-dose vial.
- **Buffer stock:** The buffer stock is recalculated every year as 25% the current vaccine requirement
- **Anticipated vaccines in stock at start of year 2006:** It is calculated by counting the current balance of vaccines in stock, including the balance of buffer stock. Write zero if all vaccines supplied for the current year (including the buffer stock) are expected to be consumed before the start of next year. Countries with very low or no vaccines in stock must provide an explanation of the use of the vaccines.
- **AD syringes:** A wastage factor of 1.11 is applied to the total number of vaccine doses requested from the Fund, excluding the wastage of vaccines.
- **Reconstitution syringes:** it applies only for lyophilized vaccines. Write zero for other vaccines.
- **Safety boxes:** A multiplying factor of 1.11 is applied to safety boxes to cater for areas where one box will be used for less than 100 syringes

### 3.4 Confirmed/ revised request for injection safety support for the year 2006

**Table 6: Estimated supplies for safety of vaccination for the next 2006 year**

**Table 4: with BCG vaccine**

|          |   | Formula            | For 2006 |
|----------|---|--------------------|----------|
| <b>A</b> | Target if children for BCG vaccination                        | #                  | 113,730  |
| <b>B</b> | Number of doses per child (for TT: target of pregnant women)  | #                  | 1        |
| <b>C</b> | Number of ...doses  | A x B              | 113,730  |
| <b>D</b> | AD syringes (+10% wastage)                                    | C x 1.11           | 126,240  |
| <b>E</b> | AD syringes buffer stock <sup>2</sup>                         | D x 0.25           | 31,560   |
| <b>F</b> | Total AD syringes   | D + E              | 157,800  |
| <b>G</b> | Number of doses per vial                                      | #                  | 20       |
| <b>H</b> | Vaccine wastage factor <sup>4</sup>                           | Either 2 or 1.6    | 2        |
| <b>I</b> | Number of reconstitution syringes (+10% wastage) <sup>3</sup> | C x H X 1.11/G     | 12,624   |
| <b>J</b> | Number of safety boxes (+10% of extra need)                   | (F + I) x 1.11/100 | 1,892    |

- 1 Contribute to a maximum of 2 doses for Pregnant Women (estimated as total births)
- 2 The buffer stock for vaccines and AD syringes is set at 25%. This is added to the first stock of doses required to introduce the vaccination in any given geographic area. Write zero for other years.
- 3 Only for lyophilized vaccines. Write zero for other vaccines.
- 4 Standard wastage factor will be used for calculation of reconstitution syringes. It will be 2 for BCG, 1.6 for measles and YF

**Table 5: with DPT vaccine**

|          |  | <b>Formula</b>     | <b>For 2006</b> |
|----------|--|--------------------|-----------------|
| <b>A</b> | Target if children for DPT vaccination             | #                  | 113,730         |
| <b>B</b> | Number of doses per child                          | #                  | 4               |
| <b>C</b> | Number of ...doses                                 | A x B              | 454,920         |
| <b>D</b> | AD syringes (+10% wastage)                         | C x 1.11           | 504,961         |
| <b>E</b> | AD syringes buffer stock 2                         | D x 0.25           | 126,240         |
| <b>F</b> | Total AD syringes                                  | D + E              | 631,202         |
| <b>G</b> | Number of doses per vial                           | #                  | 10              |
| <b>H</b> | Vaccine wastage factor 4                           | Either 2 or 1.6    | 2               |
| <b>I</b> | Number of reconstitution syringes (+10% wastage) 3 | C x H X 1.11/G     |                 |
| <b>J</b> | Number of safety boxes (+10% of extra need)        | (F + I) x 1.11/100 | 7,006           |

- 1 Contribute to a maximum of 2 doses for Pregnant Women (estimated as total births)
- 2 The buffer stock for vaccines and AD syringes is set at 25%. This is added to the first stock of doses required to introduce the vaccination in any given geographic area. Write zero for other years.
- 3 Only for lyophilized vaccines. Write zero for other vaccines.
- 4 Standard wastage factor will be used for calculation of reconstitution syringes. It will be 2 for BCG, 1.6 for measles and YF

**Table 6: with Measles vaccine**

|          |  | <b>Formula</b>     | <b>For 2006</b> |
|----------|--|--------------------|-----------------|
| <b>A</b> | Target if children for BCG vaccination                       | #                  | 113,730         |
| <b>B</b> | Number of doses per child (for TT: target of pregnant women) | #                  | 1               |
| <b>C</b> | Number of ....doses  | A x B              | 113,730         |
| <b>D</b> | AD syringes (+10% wastage)                                   | C x 1.11           | 126,240         |
| <b>E</b> | AD syringes buffer stock 2                                   | D x 0.25           | 31,560          |
| <b>F</b> | Total AD syringes  | D + E              | 157,800         |
| <b>G</b> | Number of doses per vial                                     | #                  | 10              |
| <b>H</b> | Vaccine wastage factor 4                                     | Either 2 or 1.6    | 2               |
| <b>I</b> | Number of reconstitution syringes (+10% wastage) 3           | C x H X 1.11/G     | 20,198          |
| <b>J</b> | Number of safety boxes (+10% of extra need)                  | (F + I) x 1.11/100 | 1,976           |

- 1 Contribute to a maximum of 2 doses for Pregnant Women (estimated as total births)
- 2 The buffer stock for vaccines and AD syringes is set at 25%. This is added to the first stock of doses required to introduce the vaccination in any given geographic area. Write zero for other years.
- 3 Only for lyophilized vaccines. Write zero for other vaccines.
- 4 Standard wastage factor will be used for calculation of reconstitution syringes. It will be 2 for BCG, 1.6 for measles and YF

*If quantity of current request differs from the GAVI letter of approval, please present the justification for that difference.*

**4. Please report on progress since submission of the last Progress Report based on the indicators selected by your country in the proposal for GAVI/IF support**

| Indicators | Targets | Achievements | Constraints | Updated targets |
|------------|---------|--------------|-------------|-----------------|
|            |         |              |             |                 |

**5. Checklist**

Checklist of completed form:

| Form Requirement:   | Completed | Comments |
|---|-----------|----------|
| Date of submission  | 10.04.05  |          |
| Reporting Period (consistent with previous calendar year)         | 2004      |          |
| Table 1 filled-in   |           |          |
| DQA reported on   |           |          |
| Reported on use of 100,000 US\$                                   |           |          |
| Injection Safety Reported on                                      |           |          |
| FSP Reported on (progress against country FSP indicators)         | Yes       |          |
| Table 2 filled-in   | Yes       |          |
| New Vaccine Request completed                                     | Yes       |          |
| Revised request for injection safety completed (where applicable) |           |          |
| ICC minutes attached to the report                                |           |          |
| Government signatures   |           |          |
| ICC endorsed  |           |          |

**6. Comments**

ICC/RWG comments:

Considering the low density of population and sparseness of vaccination points and as a result high wastage factor, and we need of delivery of 50 percent in one-dose vials, i.e. 199,916 doses.

## 7. Signatures


For the Government of Turkmenistan

Signature:  Leyli Shamuradova

Title: Deputy Minister of Health and Medical Industry.

Date: 10<sup>th</sup> April 2005

We, the undersigned members of the Inter-Agency Co-ordinating Committee endorse this report. Signature of endorsement of this document does not imply any financial (or legal) commitment on the part of the partner agency or individual.

| Agency/Organisation  | Name/Title  | Date      | Signature   | Agency/Organisation                             | Name/Title  | Date       | Signature   |
|--|---|-----------|---|---|---|------------|---|
| 1.The State Sanitary and Epidemiological Inspection of the Ministry of Health and Medical Industry | Annamurad Orazov- Deputy Head; ICC Chairman                                   |           |               | 5.UNICEF  | Enegul Djumaeva- APO MCH  |            | <br>18.04.05 |
| 2. The State Sanitary and Epidemiological Inspection   | Sophia Alieva- Head of Epidemiological Surveillance Department; ICC Secretary | 10.04.05  |                | 6.WHO Liaison Office                            | Bahtygul Karryeva- Officer  | 14.04.2005 |              |
| 3.The Ministry of Health and Medical Industry  | Guljermal Ezizova- Head of Treatment and Preventive Aid                       | 14.04.05. |               | 7.USAID   | Elena Samarkina- Health Manager   | 18.04.2005 |              |
| 4.UNFPA  | Eziz Hellenov - Assistant Representative                                      |           | <br>18.04.05 | 8.National Institute of Statistics and Forecast | Raya Magerramova- Deputy Head of Social statistics and Life level of population | 18.04.2005 |            |